StockWatch
·

Anlon Healthcare Ltd Q2 FY27 Results

AHCLQ2 FY27 Results
Filing
Result:Good· Market: Up#Broad based#Margin squeeze

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)vs Q1 FY27
Revenue105.6120.6%
Total Income105.6620.6%
Expenditure82.1811.1%
PBT23.4771.8%
Net Profit17.18107.4%
OPM23.90%6.09pp
NPM16.26%6.81pp
EPS0.32100.0%
View full financials

Revenue more than doubled YoY (102%) with PAT up 84% driven by core business growth, but OPM/NPM both contracted versus year-ago, tempering an otherwise standout quarter to a strong-but-not-peak result for a pharma intermediate maker.

ANLON HEALTHCARE · Q2 FY27 · THE VERDICT

Revenue Flying, Margins Grounded—Can Anlon Restore Both?

Q2 delivered 102% revenue growth and is tracking to full-year guidance, but EBITDA margin came in at 23.9% versus the promised 25–30%. That's not a one-time miss—it's an operational test of management's execution credibility going into FY28.

06 Nov 2026 · 6 min read
Revenue

₹105.6 Cr

+102% YoY

EBITDA margin

23.9%

vs 25–30% guidance

PAT

₹17.2 Cr

+84% YoY

H1 revenue track

₹193.17 Cr

on pace for ₹380–400 Cr FY27

The headline reads textbook: double-digit revenue growth, PAT up 84%. But there's a wedge between the result and the guidance. EBITDA margin landed at 23.9%—a 110 basis point miss against the promised 25–30% range. That's not a rounding error or a segment mix shift. It's an operational shortfall, and while management's explanation—raw material pricing in a geopolitical crunch—is credible, it's not bulletproof. The question now is whether the recovery to 25–27% by year-end actually happens, or whether this marks a structural shift in Anlon's profitability profile.

Where the margin miss sits

EBITDA margin, %
010.2720.5330.823.9Q2 actual27.5Guidance midpoint25Lower guidance bound
Q2 EBITDA margin at 23.9% fell 110 basis points short of the 25–30% guidance midpoint. Management attributes this to raw material inflation (crude, petrochemical solvents) post-geopolitical shock and consolidation of acquired Apiqo Organics, which carries a 20–23% EBITDA margin versus the Anlon core of 25–27%.

Raw material pricing pressure is real. The earnings call confirms Anlon cited geopolitical disruption driving crude and solvents pricing. This is an external headwind, not an operational slip. But it's also a risk that persists. Price revisions to customers are underway—management expects to see the benefit by Q3–Q4—but the company won't control the pace of raw material normalization.

Acquisition drag is structural, not temporary. Apiqo Organics (43.7% of H1 revenue) and Biozotic (11.7%) are integrating at lower margins than the Anlon Healthcare core. This was disclosed at acquisition time, but Q2 marks the first time we see it hit consolidated numbers. The drag is real; recovery depends on operational improvements and product mix shifts at those businesses, not just external price normalization.

Management's key claims vs. what holds up

Revenue growth 102% YoY, ₹105.61 Cr

Metric

₹105.6 Cr vs prior ₹52.2 Cr

Actual

102.3% growth

Supported

PAT growth 84.4% YoY, ₹17.18 Cr

Metric

₹17.2 Cr vs prior ₹9.32 Cr

Actual

84.4% growth

Supported

EBITDA margin 25–30% recovery target

Metric

Q2 actual 23.9% vs 25–30% range

Actual

110 bps miss; management targeting 25–27% by year-end

Overstated

FY27 guidance ₹380–400 Cr on track

Metric

H1 ₹193.17 Cr

Actual

At midpoint run-rate, tracking minimum ₹380 Cr

Supported

Consolidated capacity 1,900–2,000 MT, 65–67% utilization

Metric

Anlon stand-alone 85–86%, acquired businesses 60–65%

Actual

Management states consolidated at 65–67%

Supported

FY28 ₹650–700 Cr growth backed by 1,200 MT expansion Q1 FY28

Metric

67–80% growth from current quarterly run-rate

Actual

Rajkot greenfield under construction; first floor completion targeted end-Nov

Supported but execution-dependent

What changed on this call

FY28 revenue guidance raised to ₹650–700 Cr (new). Prior guidance was FY27 only. This implies 67–80% growth from current quarterly run-rate—aggressive but grounded in concrete capacity (1,200 MT expansion commissioning Q1 FY28). Explicitly excludes CDMO first revenue and medical device ramp-up, de-risking the projection.

CDMO commercial supply timeline slipped by 1–2 months. From "Q3 FY27" to "end-Q3 or early-Q4." First molecule validation is complete, but customer ramp-up timing is now the binding constraint. This is a minor slip, but it signals execution risk in new revenue streams when management promised visibility.

Capital raise formalized and fast-tracked. ₹65–70 Cr equity raise approval received in November; allotment expected within 8–10 days. Funds allocated to capex (₹130 Cr total, ₹70 Cr debt-funded) and acquisitions. This de-risks the Rajkot expansion funding but ties execution to equity dilution and integration burn.

Margin guidance maintained but now at risk. Prior call (Q1): management was confident in 25–30% stabilization. Q2 actual: 23.9%. Management now targeting 25–27% (narrower range, lower floor) by year-end. This is a silent downgrade—the confidence envelope has tightened, and management has retreated from the upper bound.

The bull-bear ledger

  • Revenue growth is real and strong (102% YoY, ₹105.6 Cr). Not a one-quarter pop.

  • H1 tracking to full-year FY27 guidance (₹193 Cr toward ₹380–400 Cr). Guidance discipline intact.

  • FY28 growth target (₹650–700 Cr) backed by concrete 1,200 MT capacity expansion, not vaporware.

  • Positioned in China Plus One narrative: cost ~10% below Chinese suppliers, regulatory moat (DMF approvals, registrations).

  • International regulatory progress (PMDA Japan, NMPA China, EDQM Europe approvals for Loxoprofen variants).

  • EBITDA margin 23.9% vs 25–30% guidance is a 110 bps operational miss, not excused by one-time items.

  • Acquisitions (Apiqo 43.7% of revenue, Biozotic 11.7%) integrating at 20–23% EBITDA margin vs. core 25–27%. Consolidated drag is structural.

  • New revenue streams (CDMO, Medicos, Loxoprofen ointment) delayed or minimal in FY27; FY28 uplift depends on execution.

  • Operating cash flow H1 ₹7.94 Cr (vs ₹79.44 Cr prior). Working capital cycle stressed; receivables at 123 days, payables 40 days.

  • Raw material pricing (crude, solvents) normalization uncertain; geopolitical pressure may persist.

Risks ranked by how much they should concern a holder

Key risks, prioritized by severity and investor impact

Margin compression vs guidance (23.9% actual vs 25–30% target)

High

EBITDA margin miss is 110 bps and directly impacts profitability. If not recovered by year-end, it signals a structural shift in cost structure or pricing power. Acquisition drag (Apiqo 20–23% vs core 25–27%) persists; external raw material normalization may not deliver expected relief.

New revenue streams (CDMO, Medicos, Loxoprofen ointment) delayed or unproven

High

FY28 ₹650–700 Cr guidance explicitly excludes these pending clarity. If delayed further or underperform, growth target misses. CDMO first commercial supply pushed Q3→Q4; Medicos minimal FY27 revenue; Loxoprofen DCGI approval timing uncertain.

Acquisition integration drag (Apiqo, Biozotic) on consolidated profitability

Medium

Apiqo (43.7% of H1 revenue) and Biozotic (11.7%) integrate at 20–23% EBITDA margin. ROE dilution evident; management says improvement by FY28 but no proof yet. If integration stalls, consolidated margin stays depressed.

Capacity expansion execution (Rajkot 1,200 MT, Q1 FY28 commissioning)

Medium

Core to FY28 growth story. Under construction, first floor on track, but regulatory approval risk mentioned (1–2 month possible delay). Any delay pushes new capacity revenue into FY28 H2+, testing growth targets.

Regulatory approval delays (7 DMF filings, Loxoprofen ointment DCGI, Ketoprofen US)

Medium

DMF filing progress on track (3 of 7 done, 6 by year-end targeted), but Ketoprofen US on hold, Loxoprofen DCGI timing vague. Delays push commercialization into FY28+.

Raw material pricing persistence (crude, petrochemical solvents)

Medium

Geopolitical situation cited; normalization uncertain. Q2 margin miss attributed to this; if pricing doesn't normalize, even FY28 margin recovery target (25–27%) at risk.

Working capital cycle stress (123-day receivables, 40-day payables)

Low

Management improving but cycle still elevated versus 170–180 day target. Strains cash availability for capex and growth investments. Addressable through credit control and supplier terms.

How the street is positioned

The stock sits at ₹27.99, down 83.8% from its all-time high of ₹172.75, but trading above its SMA20 (₹26.53), SMA50 (₹24.25), and SMA200 (₹20.41). This tells two stories: the drawdown was sharp and deep, but recovery momentum is real. RSI at 57.3 (neutral) suggests no extreme overbought or oversold condition.

FII ownership rose to 1.67% in Q1 FY27 (from 0.32% in Q4 FY26), a 135 basis point jump. This signals recent institutional entry, though absolute position remains modest. DII trimmed from 4.60% to 1.22%—a significant pullback. Promoter stake unchanged at 52.68%, showing no insider selling signal.

Bulk block activity over the last 6 months shows Neo Apex engaging in both buys and sells across a ₹26–36 range—a pattern suggesting tactical trading rather than conviction. No promoter-linked selling near the highs. The depth of institutional positioning is still building.

The disconnect is instructive: the stock has recovered 170% off its low but lost 84% from its high. Q2's 102% revenue growth and strong H1 track record should spark a positive catalyst, but the margin miss (23.9% vs 25–30% guidance) appears to be dampening the rally. The market is pricing in caution until management proves margin recovery is real, not just a promise. In other words: growth is believed; profitability is not—yet.

The debate

What to watch next

The 3 catalysts that resolve the debate
  • 1 · Q3 FY27 EBITDA margin (Nov–Dec 2026 results)

    Will management deliver on the 25–27% recovery target, or stay at 23–24%? This is the single most important metric. If margins improve sequentially (above 24.5%), raw material normalization and price revisions are working. If flat or lower, the miss becomes structural, not temporary.

  • 2 · Rajkot expansion commissioning (Q1 FY28 target, Apr–Jun 2027)

    Does the 1,200 MT capacity ramp on time, or slip? On-time execution validates FY28 ₹650–700 Cr guidance credibility. Any delay >1 month raises execution concerns and forces FY28 guidance revision down.

  • 3 · CDMO first commercial revenue (Q4 FY27, Jan–Mar 2027)

    Does molecule 1 commercialize on the promised Q4 timeline, and what is the first-quarter contribution? This signals platform readiness and validates management's de-risked FY28 projection (which excludes CDMO pending clarity).

Anlon Healthcare is a genuine growth story: 102% revenue growth, positioned in a structural tailwind (India API outsourcing, China Plus One), and backed by real new capacity coming online. But Q2 raised the stakes. The margin miss (23.9% vs 25–30% guidance) is not excused by one-time items or segment mix—it's operational, and it's credibility-testing. Management's job now is not to grow faster; it's to prove it can grow AND maintain profitability while integrating acquisitions and launching new products.

The number to track from here is Q3 EBITDA margin. If it recovers above 25%, the story is "growth with margin discipline." If it stays at 23–24%, the story shifts to "growth at the cost of profitability," and the valuation case changes. Until management proves it, a Hold is the honest read. The upside is real. So is the risk.

Informational and educational content only. Not investment advice.